Price T Rowe Associates Inc Clovis Oncology, Inc. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $39,427 - $107,017	-37,550 Reduced 30.42%	85,900 $103,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $31,178 - $146,490	-49,490 Reduced 28.62%	123,450 $222,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $18,733 - $41,134	13,100 Added 8.2%	172,940 $349,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $161,460 - $284,648	59,800 Added 59.78%	159,840 $433,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $91,942 - $131,346	22,646 Added 29.26%	100,040 $446,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $22,569 - $31,696	-4,496 Reduced 5.49%	77,394 $449,000
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $41,385 - $88,965	8,604 Added 11.74%	81,890 $575,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $302,671 - $469,763	73,286 New	73,286 $352,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.